Oramed Pharmaceuticals (ORMP) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Oramed Pharmaceuticals (NASDAQ:ORMP) is set to release its earnings on August 13th, with analysts predicting a loss of ($0.01) per share for the quarter.
• In its previous earnings report, Oramed missed expectations, reporting a loss of ($0.19) EPS and generating $2.00 million in revenue.
• Jane Street Group LLC increased its stake in Oramed by 35.3%, now holding approximately 0.16% of the company, indicating growing institutional interest.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. On average, analysts expect Oramed Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oramed Pharmaceuticals Trading Up 0.5%

Oramed Pharmaceuticals stock traded up $0.01 during midday trading on Friday, hitting $2.09. The stock had a trading volume of 36,346 shares, compared to its average volume of 69,867. The firm's fifty day moving average is $2.16 and its two-hundred day moving average is $2.22. The company has a market capitalization of $85.37 million, a PE ratio of -4.75 and a beta of 1.60. Oramed Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $3.09.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 17th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. Jane Street Group LLC grew its position in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 35.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 67,173 shares of the biotechnology company's stock after acquiring an additional 17,510 shares during the quarter. Jane Street Group LLC owned about 0.16% of Oramed Pharmaceuticals worth $144,000 at the end of the most recent reporting period. Institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.